世界のCXCR4拮抗薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global CXCR4 Antagonists Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5686
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、CXCR4拮抗薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（BL-8040、GMI-1359、プレリキサフォル（AMD3100）、バリキサフォルチド（POL6326）、USL311、その他）、用途別市場規模（がん、HIV、慢性炎症性疾患）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・CXCR4拮抗薬の市場動向
・企業の競争状況、市場シェア
・CXCR4拮抗薬の種類別市場規模と予測2016-2027（BL-8040、GMI-1359、プレリキサフォル（AMD3100）、バリキサフォルチド（POL6326）、USL311、その他）
・CXCR4拮抗薬の用途別市場規模と予測2016-2027（がん、HIV、慢性炎症性疾患）
・CXCR4拮抗薬の北米市場規模2016-2027（アメリカ、カナダ）
・CXCR4拮抗薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・CXCR4拮抗薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・CXCR4拮抗薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・CXCR4拮抗薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Sanofi、BioLineRx、X4 Pharmaceuticals、Eli Lilly、Roche、Merck、Biokine Therapeutics、GlycoMimetics、Harmonic Pharma、Upsher-Smith Laboratories）
・結論

CXCR4 antagonists are small-molecule which block the CXCR4 receptors and prevent their activation. Blocking the receptors stop the receptors’ ligand, CXCL12, from binding which prevent downstream effects. CXCR4 antagonists are especially important for hindering cancer progression because one of the downstream effects initiated by CXCR4 receptor activation is cell movement which lead to tumor growth and metastasis in cancer patients. The CXCR4 receptor has been targeted by antagonistic substances, these antagonists have prospective use as therapeutic drug agents, and are currently under development in labs worldwide.

Market Analysis and Insights: Global CXCR4 Antagonists Market
The global CXCR4 Antagonists market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CXCR4 Antagonists market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CXCR4 Antagonists market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CXCR4 Antagonists market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CXCR4 Antagonists market.

Global CXCR4 Antagonists Scope and Market Size
CXCR4 Antagonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CXCR4 Antagonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Others

Segment by Application
Cancer
HIV
Chronic Inflammatory Diseases

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sanofi
BioLineRx
X4 Pharmaceuticals
Eli Lilly
Roche
Merck
Biokine Therapeutics
GlycoMimetics
Harmonic Pharma
Upsher-Smith Laboratories

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CXCR4 Antagonists Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 BL-8040
1.2.3 GMI-1359
1.2.4 Plerixafor (AMD3100)
1.2.5 Balixafortide (POL6326)
1.2.6 USL311
1.2.7 Others
1.3 Market by Application
1.3.1 Global CXCR4 Antagonists Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cancer
1.3.3 HIV
1.3.4 Chronic Inflammatory Diseases
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global CXCR4 Antagonists Market Perspective (2016-2027)
2.2 CXCR4 Antagonists Growth Trends by Regions
2.2.1 CXCR4 Antagonists Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 CXCR4 Antagonists Historic Market Share by Regions (2016-2021)
2.2.3 CXCR4 Antagonists Forecasted Market Size by Regions (2022-2027)
2.3 CXCR4 Antagonists Industry Dynamic
2.3.1 CXCR4 Antagonists Market Trends
2.3.2 CXCR4 Antagonists Market Drivers
2.3.3 CXCR4 Antagonists Market Challenges
2.3.4 CXCR4 Antagonists Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top CXCR4 Antagonists Players by Revenue
3.1.1 Global Top CXCR4 Antagonists Players by Revenue (2016-2021)
3.1.2 Global CXCR4 Antagonists Revenue Market Share by Players (2016-2021)
3.2 Global CXCR4 Antagonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by CXCR4 Antagonists Revenue
3.4 Global CXCR4 Antagonists Market Concentration Ratio
3.4.1 Global CXCR4 Antagonists Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CXCR4 Antagonists Revenue in 2020
3.5 CXCR4 Antagonists Key Players Head office and Area Served
3.6 Key Players CXCR4 Antagonists Product Solution and Service
3.7 Date of Enter into CXCR4 Antagonists Market
3.8 Mergers & Acquisitions, Expansion Plans

4 CXCR4 Antagonists Breakdown Data by Type
4.1 Global CXCR4 Antagonists Historic Market Size by Type (2016-2021)
4.2 Global CXCR4 Antagonists Forecasted Market Size by Type (2022-2027)

5 CXCR4 Antagonists Breakdown Data by Application
5.1 Global CXCR4 Antagonists Historic Market Size by Application (2016-2021)
5.2 Global CXCR4 Antagonists Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America CXCR4 Antagonists Market Size (2016-2027)
6.2 North America CXCR4 Antagonists Market Size by Type
6.2.1 North America CXCR4 Antagonists Market Size by Type (2016-2021)
6.2.2 North America CXCR4 Antagonists Market Size by Type (2022-2027)
6.2.3 North America CXCR4 Antagonists Market Size by Type (2016-2027)
6.3 North America CXCR4 Antagonists Market Size by Application
6.3.1 North America CXCR4 Antagonists Market Size by Application (2016-2021)
6.3.2 North America CXCR4 Antagonists Market Size by Application (2022-2027)
6.3.3 North America CXCR4 Antagonists Market Size by Application (2016-2027)
6.4 North America CXCR4 Antagonists Market Size by Country
6.4.1 North America CXCR4 Antagonists Market Size by Country (2016-2021)
6.4.2 North America CXCR4 Antagonists Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe CXCR4 Antagonists Market Size (2016-2027)
7.2 Europe CXCR4 Antagonists Market Size by Type
7.2.1 Europe CXCR4 Antagonists Market Size by Type (2016-2021)
7.2.2 Europe CXCR4 Antagonists Market Size by Type (2022-2027)
7.2.3 Europe CXCR4 Antagonists Market Size by Type (2016-2027)
7.3 Europe CXCR4 Antagonists Market Size by Application
7.3.1 Europe CXCR4 Antagonists Market Size by Application (2016-2021)
7.3.2 Europe CXCR4 Antagonists Market Size by Application (2022-2027)
7.3.3 Europe CXCR4 Antagonists Market Size by Application (2016-2027)
7.4 Europe CXCR4 Antagonists Market Size by Country
7.4.1 Europe CXCR4 Antagonists Market Size by Country (2016-2021)
7.4.2 Europe CXCR4 Antagonists Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific CXCR4 Antagonists Market Size (2016-2027)
8.2 Asia-Pacific CXCR4 Antagonists Market Size by Type
8.2.1 Asia-Pacific CXCR4 Antagonists Market Size by Type (2016-2021)
8.2.2 Asia-Pacific CXCR4 Antagonists Market Size by Type (2022-2027)
8.2.3 Asia-Pacific CXCR4 Antagonists Market Size by Type (2016-2027)
8.3 Asia-Pacific CXCR4 Antagonists Market Size by Application
8.3.1 Asia-Pacific CXCR4 Antagonists Market Size by Application (2016-2021)
8.3.2 Asia-Pacific CXCR4 Antagonists Market Size by Application (2022-2027)
8.3.3 Asia-Pacific CXCR4 Antagonists Market Size by Application (2016-2027)
8.4 Asia-Pacific CXCR4 Antagonists Market Size by Region
8.4.1 Asia-Pacific CXCR4 Antagonists Market Size by Region (2016-2021)
8.4.2 Asia-Pacific CXCR4 Antagonists Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America CXCR4 Antagonists Market Size (2016-2027)
9.2 Latin America CXCR4 Antagonists Market Size by Type
9.2.1 Latin America CXCR4 Antagonists Market Size by Type (2016-2021)
9.2.2 Latin America CXCR4 Antagonists Market Size by Type (2022-2027)
9.2.3 Latin America CXCR4 Antagonists Market Size by Type (2016-2027)
9.3 Latin America CXCR4 Antagonists Market Size by Application
9.3.1 Latin America CXCR4 Antagonists Market Size by Application (2016-2021)
9.3.2 Latin America CXCR4 Antagonists Market Size by Application (2022-2027)
9.3.3 Latin America CXCR4 Antagonists Market Size by Application (2016-2027)
9.4 Latin America CXCR4 Antagonists Market Size by Country
9.4.1 Latin America CXCR4 Antagonists Market Size by Country (2016-2021)
9.4.2 Latin America CXCR4 Antagonists Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa CXCR4 Antagonists Market Size (2016-2027)
10.2 Middle East & Africa CXCR4 Antagonists Market Size by Type
10.2.1 Middle East & Africa CXCR4 Antagonists Market Size by Type (2016-2021)
10.2.2 Middle East & Africa CXCR4 Antagonists Market Size by Type (2022-2027)
10.2.3 Middle East & Africa CXCR4 Antagonists Market Size by Type (2016-2027)
10.3 Middle East & Africa CXCR4 Antagonists Market Size by Application
10.3.1 Middle East & Africa CXCR4 Antagonists Market Size by Application (2016-2021)
10.3.2 Middle East & Africa CXCR4 Antagonists Market Size by Application (2022-2027)
10.3.3 Middle East & Africa CXCR4 Antagonists Market Size by Application (2016-2027)
10.4 Middle East & Africa CXCR4 Antagonists Market Size by Country
10.4.1 Middle East & Africa CXCR4 Antagonists Market Size by Country (2016-2021)
10.4.2 Middle East & Africa CXCR4 Antagonists Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi CXCR4 Antagonists Introduction
11.1.4 Sanofi Revenue in CXCR4 Antagonists Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 BioLineRx
11.2.1 BioLineRx Company Details
11.2.2 BioLineRx Business Overview
11.2.3 BioLineRx CXCR4 Antagonists Introduction
11.2.4 BioLineRx Revenue in CXCR4 Antagonists Business (2016-2021)
11.2.5 BioLineRx Recent Development
11.3 X4 Pharmaceuticals
11.3.1 X4 Pharmaceuticals Company Details
11.3.2 X4 Pharmaceuticals Business Overview
11.3.3 X4 Pharmaceuticals CXCR4 Antagonists Introduction
11.3.4 X4 Pharmaceuticals Revenue in CXCR4 Antagonists Business (2016-2021)
11.3.5 X4 Pharmaceuticals Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly CXCR4 Antagonists Introduction
11.4.4 Eli Lilly Revenue in CXCR4 Antagonists Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche CXCR4 Antagonists Introduction
11.5.4 Roche Revenue in CXCR4 Antagonists Business (2016-2021)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck CXCR4 Antagonists Introduction
11.6.4 Merck Revenue in CXCR4 Antagonists Business (2016-2021)
11.6.5 Merck Recent Development
11.7 Biokine Therapeutics
11.7.1 Biokine Therapeutics Company Details
11.7.2 Biokine Therapeutics Business Overview
11.7.3 Biokine Therapeutics CXCR4 Antagonists Introduction
11.7.4 Biokine Therapeutics Revenue in CXCR4 Antagonists Business (2016-2021)
11.7.5 Biokine Therapeutics Recent Development
11.8 GlycoMimetics
11.8.1 GlycoMimetics Company Details
11.8.2 GlycoMimetics Business Overview
11.8.3 GlycoMimetics CXCR4 Antagonists Introduction
11.8.4 GlycoMimetics Revenue in CXCR4 Antagonists Business (2016-2021)
11.8.5 GlycoMimetics Recent Development
11.9 Harmonic Pharma
11.9.1 Harmonic Pharma Company Details
11.9.2 Harmonic Pharma Business Overview
11.9.3 Harmonic Pharma CXCR4 Antagonists Introduction
11.9.4 Harmonic Pharma Revenue in CXCR4 Antagonists Business (2016-2021)
11.9.5 Harmonic Pharma Recent Development
11.10 Upsher-Smith Laboratories
11.10.1 Upsher-Smith Laboratories Company Details
11.10.2 Upsher-Smith Laboratories Business Overview
11.10.3 Upsher-Smith Laboratories CXCR4 Antagonists Introduction
11.10.4 Upsher-Smith Laboratories Revenue in CXCR4 Antagonists Business (2016-2021)
11.10.5 Upsher-Smith Laboratories Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global CXCR4 Antagonists Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of BL-8040
Table 3. Key Players of GMI-1359
Table 4. Key Players of Plerixafor (AMD3100)
Table 5. Key Players of Balixafortide (POL6326)
Table 6. Key Players of USL311
Table 7. Key Players of Others
Table 8. Global CXCR4 Antagonists Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global CXCR4 Antagonists Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global CXCR4 Antagonists Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global CXCR4 Antagonists Market Share by Regions (2016-2021)
Table 12. Global CXCR4 Antagonists Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global CXCR4 Antagonists Market Share by Regions (2022-2027)
Table 14. CXCR4 Antagonists Market Trends
Table 15. CXCR4 Antagonists Market Drivers
Table 16. CXCR4 Antagonists Market Challenges
Table 17. CXCR4 Antagonists Market Restraints
Table 18. Global CXCR4 Antagonists Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global CXCR4 Antagonists Market Share by Players (2016-2021)
Table 20. Global Top CXCR4 Antagonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CXCR4 Antagonists as of 2020)
Table 21. Ranking of Global Top CXCR4 Antagonists Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by CXCR4 Antagonists Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players CXCR4 Antagonists Product Solution and Service
Table 25. Date of Enter into CXCR4 Antagonists Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 28. Global CXCR4 Antagonists Revenue Market Share by Type (2016-2021)
Table 29. Global CXCR4 Antagonists Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global CXCR4 Antagonists Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global CXCR4 Antagonists Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global CXCR4 Antagonists Revenue Market Share by Application (2016-2021)
Table 33. Global CXCR4 Antagonists Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global CXCR4 Antagonists Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 36. North America CXCR4 Antagonists Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America CXCR4 Antagonists Market Size by Application (2016-2021) (US$ Million)
Table 38. North America CXCR4 Antagonists Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America CXCR4 Antagonists Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America CXCR4 Antagonists Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe CXCR4 Antagonists Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe CXCR4 Antagonists Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe CXCR4 Antagonists Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe CXCR4 Antagonists Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe CXCR4 Antagonists Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific CXCR4 Antagonists Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific CXCR4 Antagonists Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific CXCR4 Antagonists Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific CXCR4 Antagonists Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific CXCR4 Antagonists Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America CXCR4 Antagonists Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America CXCR4 Antagonists Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America CXCR4 Antagonists Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America CXCR4 Antagonists Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America CXCR4 Antagonists Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa CXCR4 Antagonists Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa CXCR4 Antagonists Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa CXCR4 Antagonists Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa CXCR4 Antagonists Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa CXCR4 Antagonists Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa CXCR4 Antagonists Market Size by Country (2022-2027) & (US$ Million)
Table 65. Sanofi Company Details
Table 66. Sanofi Business Overview
Table 67. Sanofi CXCR4 Antagonists Product
Table 68. Sanofi Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 69. Sanofi Recent Development
Table 70. BioLineRx Company Details
Table 71. BioLineRx Business Overview
Table 72. BioLineRx CXCR4 Antagonists Product
Table 73. BioLineRx Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 74. BioLineRx Recent Development
Table 75. X4 Pharmaceuticals Company Details
Table 76. X4 Pharmaceuticals Business Overview
Table 77. X4 Pharmaceuticals CXCR4 Antagonists Product
Table 78. X4 Pharmaceuticals Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 79. X4 Pharmaceuticals Recent Development
Table 80. Eli Lilly Company Details
Table 81. Eli Lilly Business Overview
Table 82. Eli Lilly CXCR4 Antagonists Product
Table 83. Eli Lilly Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 84. Eli Lilly Recent Development
Table 85. Roche Company Details
Table 86. Roche Business Overview
Table 87. Roche CXCR4 Antagonists Product
Table 88. Roche Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 89. Roche Recent Development
Table 90. Merck Company Details
Table 91. Merck Business Overview
Table 92. Merck CXCR4 Antagonists Product
Table 93. Merck Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 94. Merck Recent Development
Table 95. Biokine Therapeutics Company Details
Table 96. Biokine Therapeutics Business Overview
Table 97. Biokine Therapeutics CXCR4 Antagonists Product
Table 98. Biokine Therapeutics Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 99. Biokine Therapeutics Recent Development
Table 100. GlycoMimetics Company Details
Table 101. GlycoMimetics Business Overview
Table 102. GlycoMimetics Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 103. GlycoMimetics Recent Development
Table 104. Harmonic Pharma Company Details
Table 105. Harmonic Pharma Business Overview
Table 106. Harmonic Pharma CXCR4 Antagonists Product
Table 107. Harmonic Pharma Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 108. Harmonic Pharma Recent Development
Table 109. Upsher-Smith Laboratories Company Details
Table 110. Upsher-Smith Laboratories Business Overview
Table 111. Upsher-Smith Laboratories CXCR4 Antagonists Product
Table 112. Upsher-Smith Laboratories Revenue in CXCR4 Antagonists Business (2016-2021) & (US$ Million)
Table 113. Upsher-Smith Laboratories Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CXCR4 Antagonists Market Share by Type: 2020 VS 2027
Figure 2. BL-8040 Features
Figure 3. GMI-1359 Features
Figure 4. Plerixafor (AMD3100) Features
Figure 5. Balixafortide (POL6326) Features
Figure 6. USL311 Features
Figure 7. Others Features
Figure 8. Global CXCR4 Antagonists Market Share by Application: 2020 VS 2027
Figure 9. Cancer Case Studies
Figure 10. HIV Case Studies
Figure 11. Chronic Inflammatory Diseases Case Studies
Figure 12. CXCR4 Antagonists Report Years Considered
Figure 13. Global CXCR4 Antagonists Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global CXCR4 Antagonists Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global CXCR4 Antagonists Market Share by Regions: 2020 VS 2027
Figure 16. Global CXCR4 Antagonists Market Share by Regions (2022-2027)
Figure 17. Global CXCR4 Antagonists Market Share by Players in 2020
Figure 18. Global Top CXCR4 Antagonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CXCR4 Antagonists as of 2020
Figure 19. The Top 10 and 5 Players Market Share by CXCR4 Antagonists Revenue in 2020
Figure 20. Global CXCR4 Antagonists Revenue Market Share by Type (2016-2021)
Figure 21. Global CXCR4 Antagonists Revenue Market Share by Type (2022-2027)
Figure 22. North America CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America CXCR4 Antagonists Market Share by Type (2016-2027)
Figure 24. North America CXCR4 Antagonists Market Share by Application (2016-2027)
Figure 25. North America CXCR4 Antagonists Market Share by Country (2016-2027)
Figure 26. United States CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe CXCR4 Antagonists Market Share by Type (2016-2027)
Figure 30. Europe CXCR4 Antagonists Market Share by Application (2016-2027)
Figure 31. Europe CXCR4 Antagonists Market Share by Country (2016-2027)
Figure 32. Germany CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific CXCR4 Antagonists Market Share by Type (2016-2027)
Figure 40. Asia-Pacific CXCR4 Antagonists Market Share by Application (2016-2027)
Figure 41. Asia-Pacific CXCR4 Antagonists Market Share by Region (2016-2027)
Figure 42. China CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America CXCR4 Antagonists Market Share by Type (2016-2027)
Figure 50. Latin America CXCR4 Antagonists Market Share by Application (2016-2027)
Figure 51. Latin America CXCR4 Antagonists Market Share by Country (2016-2027)
Figure 52. Mexico CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa CXCR4 Antagonists Market Share by Type (2016-2027)
Figure 56. Middle East & Africa CXCR4 Antagonists Market Share by Application (2016-2027)
Figure 57. Middle East & Africa CXCR4 Antagonists Market Share by Country (2016-2027)
Figure 58. Turkey CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE CXCR4 Antagonists Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Sanofi Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 62. BioLineRx Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 63. X4 Pharmaceuticals Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 64. Eli Lilly Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 65. Roche Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 66. Merck Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 67. Biokine Therapeutics Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 68. GlycoMimetics Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 69. Harmonic Pharma Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 70. Upsher-Smith Laboratories Revenue Growth Rate in CXCR4 Antagonists Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界のP2X7受容体拮抗薬市場規模・現状・予測（2021年-2027年）

Global P2X7 Receptor Antagonists Market Size, Status and Forecast 2021-2027
QFJ1-4643 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、P2X7受容体拮抗薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（GSK1482160、AZD9056、EVT 401、JNJ 55308942＆JNJ 54175446、AKP-23494954/...

世界の胃がん治療市場規模・現状・予測（2021年-2027年）

Global Stomach Cancer and Gastric Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-6022 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、胃がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プログラム細胞死タンパク質1（PD-1）阻害剤、ヒト上皮成長因子受容体（HER2）拮抗薬、血管内皮増殖因子受容体（VEGFR）拮抗薬、その他）...

世界の抗潰瘍薬市場規模・現状・予測（2021年-2027年）

Global Antiulcerant Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5591 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、抗潰瘍薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プロトンポンプ阻害剤、H2受容体拮抗薬、胃粘膜保護薬、抗生物質、制酸剤、プロスタグランジン作動薬）、用途別市場規模（口内潰瘍、胃潰瘍、下腿潰瘍、...

世界の全身性強皮症治療市場規模・現状・予測（2021年-2027年）

Global Systemic Scleroderma Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4931 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、全身性強皮症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、その他）...

世界の全身性強皮症治療薬市場規模・現状・予測（2021年-2027年）

Global Systemic Scleroderma Drugs Market Size, Status and Forecast 2021-2027
QFJ1-6029 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、全身性強皮症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、その他...

世界の非びらん性胃食道逆流症治療市場規模・現状・予測（2021年-2027年）

Global Nonerosive Reflux Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5889 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、非びらん性胃食道逆流症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プロトンポンプ阻害剤、H2受容体拮抗薬、制酸剤、その他）、用途別市場規模（小売薬局、病院薬局、オンライン薬局）、主要地域別市場...

世界の抗腫瘍薬市場規模・現状・予測（2021年-2027年）

Global Anti-Neoplastic Pharmaceutical Agents Market Size, Status and Forecast 2021-2027
QFJ1-3830 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、抗腫瘍薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホルモン＆拮抗薬、微生物製品、植物製品、抗腫瘍抗生物質、アルキル化剤、代謝拮抗剤、天然物）、用途別市場規模（肺がん、膀胱がん、乳がん、子宮頸がん...

世界の拡張型心筋症治療薬市場規模・現状・予測（2021年-2027年）

Global Dilated Cardiomyopathy Therapeutic Market Size, Status and Forecast 2021-2027
QFJ1-4136 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、拡張型心筋症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アルドステロン拮抗薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、ベータ遮断薬）、用途別市場...

世界の前立腺がん治療市場規模・現状・予測（2021年-2027年）

Global Prostate Cancer Medicine Market Size, Status and Forecast 2021-2027
QFJ1-4770 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、前立腺がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（LHRH拮抗薬、LHRHアナログ、抗アンドロゲン、ホルモン療法用パイプライン薬）、用途別市場規模（病院、その他）、主要地域別市場規模（北米...

世界のヒト免疫不全ウイルス (HIV) 治療薬市場規模・現状・予測（2021年-2027年）

Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-5787 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、ヒト免疫不全ウイルス (HIV) 治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（NRTI、NNRTI、侵入＆融合阻害剤、プロテアーゼ阻害剤、インテグラーゼ阻害剤、補助受容体拮抗剤）、用途別市場...

世界のP2X7受容体拮抗薬市場規模・現状・予測（2021年-2027年） P2X7 Receptor (P2X7R) is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines. P2X7 Receptor Antagonists can provide a novel approach to the treatm…
世界のプレリキサフォル市場規模・現状・予測（2021年-2027年） Plerixafor (INN and USAN, trade name Mozobil) is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. Market Analysis and Insights: Global Plerixafor Market The global Plerixafor market size is projected to reach US$ XX million by 2027, from US$ XX mi…
世界の慢性肝疾患治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Chronic Liver Diseases Therapeutics Market The global Chronic Liver Diseases Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and hig…
世界の胃がん治療市場規模・現状・予測（2021年-2027年） Stomach cancer is the fifth most common cancer in the world Market Analysis and Insights: Global Stomach Cancer and Gastric Cancer Treatment Market The global Stomach Cancer and Gastric Cancer Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR …
セロトニン拮抗薬のグローバル市場調査 2019年 The global Serotonin Antagonists market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Serotonin Antagonists volume and value at global level, regional level and company level. From a global perspective, …